SPECIAL GLP-1 TEST YOUR KNOWLEDGE, Part 2

Upon diagnosis, with a glycosylated hemoglobin (A1c) level of 7.3%, he was initiated on lifestyle modifications plus metformin 500 mg twice daily. Eventually his metformin was titrated up to 1000 mg twice daily. After his best attempts at diet, exercise, and adherence to metformin for 1 year, his A1c was down to 6.4%. Scott presents to you most recently, however, with a loss of glycemic control despite continued best efforts on his part. His A1c has climbed to 7.7%, and you decide it is time to initiate another antihyperglycemic agent in addition to his metformin. At this visit his body mass index is 32 kg/m², and his waist circumference is 46 inches.

For Question 1, please follow this link.

Question 2: According to the AACE/ACE Consensus Statement, which of the following contributes to the preference for GLP-1 receptor agonists over DPP4 inhibitors?

a)    DPP4 inhibitors are only available in injectable preparations, whereas GLP-1 receptor agonists are available as oral tablets.

b)    GLP-1 receptor agonists are associated with less incidence of hypoglycemia than DPP4 inhibitors

c)    While DPP4 inhibitors are neutral on weight, many patients using a GLP-1 receptor agonist will experience weight loss.

Click here for the correct answer.